Articles

The latest news for pharma industry insiders.

Pharma Pulse 4/18/24: Certain Biotech Investors Get an Early Look at Results, An Ethical Outlook for Obesity Drugs & more

A panel uncovers the value in meeting carbon-neutral goals by 2030. 

LogiPharma Europe 2024: Collaboration on Behalf of Sustainability 

Data from the Phase III APPLAUSE-IgAN study showed a 38.3% reduction in proteinuria in patients treated with Fabhalta for IgA nephropathy compared to placebo. 

Novartis’ Fabhalta Shows Significant Promise in Reducing Proteinuria in Patients with IgA Nephropathy 

Panel discussion uncovers how to alter one’s digital know-how for use in temperature-controlled supply chain. 

LogiPharma Europe 2024: A Digital Capability Transformation

Pharma Pulse 4/17/24: At-Home Patients and AI, Psychedelics Present Unique Ethical Challenges & more

Company also purchased equipment for 12 good manufacturing practice clean rooms.

BioHarvest Sciences Expands Operations with New 80,000 Square Foot Facility in Yavne, Israel

Capital also expected to assist the advancement of Evergreen's radiopharmaceutical discovery pipeline into clinical trials. 

Evergreen Theragnostics Raises $26M in Capital to Aid Commercialization Efforts for the Ga-68 DOTATOC Diagnostic Kit

Pharma Pulse 4/16/24: Diabetes Weight Loss Drugs Could Reduce Risk of MS, Walmart Health Expands in Texas & more

Results of the trial suggest that early intervention for intracerebral hemorrhage using parafascicular surgery were safe.

Trial Findings for Minimally Invasive Parafascicular Technology Show Promise for Intracerebral Hemorrhage Treatment

Phase IIa clinical trial of SPG60 for Fragile X syndrome offers hope for disease with no current FDA-approved treatment options.

News